Remove 2021 Remove Competition Remove Food and Drug Administration
article thumbnail

Can we get healthcare right?

World of DTC Marketing

Patients on Medicare who don’t qualify for low-income subsidies could see out-of-pocket costs for the drug of over $12,000. These hospitals spent $116 million on federal lobbying in 2021. A bill to lower drug prices via negotiations with Medicare is finally moving forward, but PhRMA has bought some politicians.

article thumbnail

FDA approves long-acting injectable for schizophrenia and bipolar disorder

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Rykindo ® (risperidone) for extended-release injectable suspension. The drug is indicated as a bi-weekly treatment for schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

article thumbnail

AB Science announces Canadian patent for masitinib to treat ALS

Pharmaceutical Technology

This helps to prevent generic competition for eight years after initial approval. Under the notice of compliance with conditions (NOC/c) policy, AB Science received authorisation from Health Canada to file a new drug submission for masitinib to treat ALS. According to AB Science, approximately 3,000 Canadians are now living with ALS.

article thumbnail

Lupkynis approved for the treatment of LN in the EU and UK

Pharmaceutical Technology

Notably, Lupkynis is the first oral therapy approved by the US Food and Drug Administration (FDA) and EC for the treatment of active LN. Key opinion leaders (KOLs) interviewed by GlobalData believe this may have significant impact on patients as the less-invasive route of administration will be preferred by many.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

billion in 2021, with a compounded annual growth rate (CAGR) of 3.1% Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The potential increase in industry competition could also spell trouble for some.

Medical 98
article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. First generics are the first opportunity manufacturers have to market new generic drug products in the US.